Table 2 Treatment-related adverse events

From: Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study

 

All grades

Grade 3 or worse

Any events, n (%)

37 (97.4)

20 (52.6)

Frequent events, n (%)

 Aspartate aminotransferase increased

28 (73.7)

13 (34.2)

 Alanine aminotransferase increased

25 (65.8)

7 (18.4)

 White blood cell decreased

16 (42.1)

0

 Platelet count decreased

15 (39.5)

6 (15.8)

 Neutrophil count decreased

15 (39.5)

1 (2.6)

 Gastrointestinal bleeding

16 (42.1)

1 (2.6)

 Thyroid stimulating hormone increased

14 (36.8)

0

 Hypoalbuminemia

11 (28.9)

0

 Endocrine disorders

8 (21.1)

0

 Weight loss

7 (18.4)

0

 Blood bilirubin increased

5 (13.2)

0

 Rash

5 (13.2)

0

 Hypothyroidism

6 (15.8)

0

 Hyperthyroidism

4 (10.5)

0

 Palmar-plantar erythrodysesthesia syndrome

3 (7.9)

2 (5.3)

 Hypertension

2 (5.3)

1 (2.6)

 Hypertriglyceridemia

1 (2.6)

1 (2.6)